Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
about
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsDevelopment and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Structural selectivity of human SGLT inhibitors.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Pharmacotherapy for childhood obesity: present and future prospects.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.Clinical implication of SGLT2 inhibitors in type 2 diabetes.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
P2860
Q28074843-DB47E29B-36B5-4D7A-A1A5-E45F57D300B0Q35214420-0EF3ED67-518D-4F56-A1B5-85940B3AE5E4Q35895528-FA54F69F-67F6-46A6-9829-B5746AF227CBQ35906490-123372E6-B664-4F39-A455-089EBFAC1D00Q36468087-8D119B49-693C-4AF1-9F0D-9C5757E62800Q36929947-DCD5FB24-3E5D-4981-8BBF-F6B083101B5DQ37764285-18B04C75-C414-41D3-89A4-06956CFB249AQ37872125-03763AD3-B8E8-4A76-9C2C-C774C1D277B4Q37981884-E5EDA458-2B72-4A53-85FB-ED68BAEDB6DAQ38075117-E1CF37DF-3110-4A61-B0B5-B70790B62C25Q38077305-6676EBFC-37DF-405B-8089-423C1F17F986Q38085691-B1DD1D3C-B226-45CB-9E32-8238A2F449FFQ38126109-3AB3507A-1E4A-495C-828C-AA5F146BE15AQ38130748-DB1F652B-6B22-49FC-BC7F-3062382047D3Q38196340-98E51A7D-F729-4CF3-AB4C-0BE8FDACF2D7Q38221980-70D341E2-266B-4B65-845C-5F41334014D4Q38908779-A03986B6-5D29-4A89-B322-76534B6B1AE6Q38936746-0A127489-34BB-4ADC-8D47-A068C411707AQ38975736-088EE210-BC37-4C38-877F-38517F0AB439Q39636097-87A5B939-CC7A-4B6D-A79D-9C817DB58CA7Q46207930-4D5C8884-E7E5-4991-98B8-EEB1117598E0Q47100805-5B65F412-15CE-4BE5-A60E-B28775759440
P2860
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@en
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@nl
type
label
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@en
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@nl
prefLabel
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@en
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@nl
P2093
P2860
P356
P1476
Multiple-dose pharmacokinetics ...... randomized double-blind study.
@en
P2093
Anita Kapur
Debbi Layko
Derek J R Nunez
Elizabeth K Hussey
Nancy L Stockman
Randall R Stoltz
Robert L Dobbins
Robin L O'Connor-Semmes
Sharon C Murray
P2860
P304
P356
10.1177/0091270009352185
P577
2010-03-03T00:00:00Z